Clinical trial of Cerebroprotein Hydrolysate for Injection completes

Hard to Treat Diseases (the "Company") (HTDS.PK) announced today, that its China based subsidiary Mellow Hope, has just finished (August 2009) the clinical trial of Cerebroprotein Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India.

This biological product is a unique nutriment for the brain. It helps CNS in multiple ways, regulating and improving nerve cell metabolism, promoting synapse generation, inducing nerve cell differentiation, protecting nerve cells against damages by ischemia and neurotoxins etc.

This clinical trial is a multicentre one, authorized by Mellow Hope and sponsored by our partner Lupin Limited which is one of the top 3 pharmaceutical companies in India. The aim of this trial is to evaluate the efficacy and safety of this product in the management of subjects with Dementia in an open labeled, prospective, phase-III clinical trial. Through this clinical trial, this product has been approved with very good efficacy and safety.

In other company news, the revised business plan under consideration as per the issuer's news announcement of yesterday September 3 2009 includes an anti-aging and cancer treatment project. More information about cancer treatment project will be shortly available with Slavica Bio Chem (Slavica) on the updated website Slavica is a second operating subsidiary of HTDS in Serbia, Europe. The aforementioned Mellow Hope and Lupin World clinical trial and cooperation is in addition to research work of Slavica.

Mr. Terry Yuan CEO of HTDS said (sic) "With the completion of this clinical trial, we are expected to receive the registration approval for NUTRIPROTEIN within three months in India. As soon as we get the approval, we will launch this product in the local market. Without any competitors in India, we will win a large market shares."

The issuer intends to provide further updates to its shareholders from both Mellow Hope in China and Slavica Bio Chem in Serbia operations on a frequent basis including certain developments on the anti-aging and cancer treatment project which the issuer is hopeful will have a significant and positive impact on its share price and add value to its shareholders.


  1. TJ TJ Canada says:

    Are there any feed backs from the patients on this Clinical trial of Cerebroprotein Hydrolysate for Injection completes?

  2. parul patel parul patel United States says:


    • Rohit Rao Rohit Rao India says:

      I am in the process of taking a decision to opt for this treatment for my father. I have been advised that the treatment would last for 4 weeks, wherein one unit (do not know the measure) of the medicine would be injected (through I V) everyday. I share the same questions as you guys and more importantly are there any known side effects?

  3. Sanjeev Anand Sanjeev Anand India says:

    The doctor treating my father is outstanding and he has also recommended going for cognistar injection. However, my father is also apprehensive about going for a treatment which does not have any proven efficacy. Please let me know about the efficacy of the same if you have done it for your father. I know that this is a hard time for near and dear ones. But I'am sure that if we keep in touch and exchange notes it will give us the courage and strength to see our loved one fight the disease.

  4. Rakesh Sharma Rakesh Sharma United Kingdom says:

    I have the same question and since doctors in India are prescribing Cognistar Inj. Would appreciate if any one has taken this injection should share there experience as it will
    people who are waiting to take the decision.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Prostate cancer cells gain unnatural ability to change shape and spread